Copy For Citation
Ureyen S. B., Ivory C., KALYONCU U., Karsh J., Aydin S. Z.
RHEUMATOLOGY ADVANCES IN PRACTICE, vol.2, no.1, 2018 (ESCI)
Article / Article
RHEUMATOLOGY ADVANCES IN PRACTICE
Emerging Sources Citation Index (ESCI), Scopus
psoriatic arthritis, randomized controlled trials, outcomes, axial disease, enthesitis, dactylitis, inclusion criteria, ORAL PHOSPHODIESTERASE-4 INHIBITOR, PATIENT-REPORTED OUTCOMES, QUALITY-OF-LIFE, PLACEBO-CONTROLLED TRIAL, ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY, TERM 52-WEEK IMPROVEMENTS, CURRENT SKIN INVOLVEMENT, DOUBLE-BLIND, PHASE-III, DISEASE-ACTIVITY
Hacettepe University Affiliated:
Objective. PsA is a heterogeneous disease with various subtypes of joint manifestations, which can affect the homogeneity of randomized controlled trials (RCTs). The aim of this systematic literature review was to evaluate the inclusion criteria, demographics and outcomes of RCTs to see whether the whole spectrum of PsA was represented.